Macrocyclic Compositions And Metal Complexes For Bioimaging And Biomedical Applications

Abstract

The present disclosure provides a novel class of macrocyclic compounds and their metal complexes formed with transition metal ion, lanthanide metal ions and other metal ions (e.g., Al, Ga, Y, In, Sn, Tl, Pb and Bi) and their applications in the fields of contrast agents, artificial nucleases, fluorescence probes, nuclear medicines and other biomedical applications in the therapeutics or diagnostics.

1 .- 20 . (canceled) 
     
     
         21 . A compound of formula (I): 
       
         
           
           
               
               
           
         
       
       or an enantiomer, a tautomer, a pharmaceutically acceptable salt, or a prodrug thereof; 
       wherein:
 Ar is an optionally substituted phenyl ring or a pyridine ring, an aryl or a heterocyclic ring optionally substituted with R 1 ; 
 G is N; 
 J is —CH 2 —, or —CH 2 CH 2 —; 
 L 1  is —CH 2 —, or —CH 2 CH 2 —; 
 K is —CH 2 —, or —CH 2 CH 2 —; 
 L is —C—, —S(O)—, or —P(OH)—; 
 each R 1  is independently —OH, —(CH 2 ) n OR 4 , —(CH 2 ) n -alkyl, —(CH 2 ) n -aryl, —(CH 2 ) n —N 3 ; 
 each R 2  is independently H, optionally substituted alkyl, —(CH 2 ) n -aryl, —(CH 2 ) n —N 3 ; 
 each R 3  is independently —OH, or —NHR 6 ; 
 each R 6  is independently H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or optionally substituted heterocyclic; 
 m is 2. 
 
     
     
         22 . The compound of  claim 21 , wherein the compound of formula (I) is a compound of formula (III): 
       
         
           
           
               
               
           
         
         wherein R 2  is independently H, methyl, p-methoxybenzyl, or 6-methyl-pyridien-2-carboxylic acid. 
       
     
     
         23 . The compound of  claim 21 , further comprising at least one group of formula (IV):
   —W—(X s —Y t ) p —  (IV)
   that binds to Ar of the compound of formula (I) and to a biomolecule, wherein:
 W is —CH 2 —, —SO—, —SO 2 —, —CO—, —NHNH—, —CONH—, —NHCO—, —NHCONH—, —CONHCO—, —NHCONHO—, —COO—, —COCH 2 —, —CH 2 CO—, —NHO—, —ONH—, —CH═CH—, —NH—, —NR 8 , —NH(C═NH)NH—, —CH═N—, —N═CH—, —SO 2 NH—, —NHSO 2 —, —NH—CS—, —NHCSNH—, —NH(C═NH)NH—O—, —OCO—, —S—S—, or —N═N—, R 8  is alkyl, cycloalkyl, or aryl; 
 X and Y are same or different and independently optionally substituted alkyl, cycloalkyl, aryl, or heterocylic; and
 s, t, and p are an integer from 0 to 100. 
 
   
     
     
         24 . The compound of  claim 23 , wherein X and Y further comprises negatively charged carboxylate or positively charged ammonium moieties. 
     
     
         25 . The compound of  claim 23 , wherein the biomolecule is a protein, an oligopeptide, an oligonucleotide, a modified oligopeptide or oligonucleotide, or a polymer. 
     
     
         26 . The compound of  claim 25 , wherein the modified oligopeptide or oligonucleotide is phosphoroamidate, phosphoromonothioate, or phosphorodithioate, and wherein the polymer is polyethylene glycol or polylysine, or a nanoparticle. 
     
     
         27 . A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of formula (I) or a metal complex of a compound of formula (I): 
       
         
           
           
               
               
           
         
         or an enantiomer, a tautomer, a pharmaceutically acceptable salt, or a prodrug thereof; 
         wherein:
 Ar is an optionally substituted phenyl ring or a pyridine ring, an aryl or a heterocyclic ring optionally substituted with R 1 ; 
 G is N; 
 J is —CH 2 —, or —CH 2 CH 2 —; 
 L 1  is —CH 2 —, or —CH 2 CH 2 —; 
 K is —CH 2 —, or —CH 2 CH 2 —; 
 L is —C—, —S(O)—, or —P(OH)—; 
 
         each R 1  is independently —OH, —(CH 2 ) n OR 4 , —(CH 2 ) n -alkyl, —(CH 2 ) n -aryl, —(CH 2 ) n —N 3 ; 
         each R 2  is independently H, optionally substituted alkyl, —(CH 2 ) n -aryl, —(CH 2 ) n —N 3 ; 
         each R 3  is independently —OH, or —NHR 6 ; 
         each R 6  is independently H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or optionally substituted heterocyclic; 
         m is 2. 
       
     
     
         28 . The pharmaceutical composition of  claim 27 , wherein the compound of formula (I) further comprises at least one group of formula (IV):
   —W—(X s —Y t )—  (IV)
   that binds to Ar of the compound of formula (I) and to a biomolecule, wherein:   W is —CH 2 —, —SO—, —SO 2 —, —CO—, —NHNH—, —CONH—, —NHCO—, —NHCONH—, —CONHCO—, —NHCONHO—, —COO—, —COCH 2 —, —CH 2 CO—, —NHO—, —ONH—, —CH═CH—, —NH—, —NR 8 , —NH(C═NH)NH—, —CH═N—, —N═CH—, —SO 2 NH—, —NHSO 2 —, —NH—CS—, —NHCSNH—, —NH(C═NH)NH—O—, —OCO—, —S—S—, or —N═N—   R 8  is alkyl, cycloalkyl, or aryl;   X and Y are same or different and independently optionally substituted alkyl, cycloalkyl, aryl, or heterocylic; and   s, t, and p are an integer from 0 to 100.   
     
     
         29 . The pharmaceutical composition of  claim 28 , wherein X and Y further comprises negatively charged carboxylate or positively charged ammonium moieties. 
     
     
         30 . The pharmaceutical composition of  claim 28 , wherein the biomolecule is a protein, an oligopeptide, an oligonucleotide, a modified oligopeptide or oligonucleotide, or a polymer. 
     
     
         31 . The pharmaceutical composition of  claim 28 , wherein the modified oligopeptide or oligonucleotide is phosphoroamidate, phosphoromonothioate, or phosphorodithioate, and wherein the polymer is polyethylene glycol or polylysine, or a nanoparticle.